By Adebola Isimijola, Lagos

The National Agency for Food and Drug Administration and Control (NAFDAC) has blacklisted Onifam Laboratories Ltd, its Managing Director/Chief Executive Officer, all directors and affiliated or associated persons and entities over what it described as serious regulatory violations.

The blacklist, which takes immediate effect, followed extensive investigations that uncovered regulatory misrepresentation, misuse of NAFDAC approvals and certificates, improper registration and transfer of pharmaceutical products, and activities that circumvented established regulatory processes.

The agency disclosed this in a press statement issued on Monday, July 20, 2026, and signed by its Director-General/Chief Executive Officer, Prof. Mojisola Adeyeye.

According to NAFDAC, the violations compromise product traceability, weaken accountability and pose significant risks to public health, contrary to the provisions of the NAFDAC Act, the Food, Drug and Related Products (Registration, etc.) Act, the Drug and Related Products Registration Regulations 2021, and other applicable regulatory guidelines.

“The decision follows extensive investigations which established that the company engaged in regulatory misrepresentation, misuse of NAFDAC approvals and certificates, improper registration and transfer of pharmaceutical products, and activities that circumvented established regulatory processes,” the statement said.

NAFDAC said the company and all affected persons or entities are prohibited from participating, directly or indirectly, in any pharmaceutical business regulated by the agency.

It added that the ban covers applying for or benefiting from any NAFDAC registration, licence, permit, certificate or approval, as well as acting as manufacturers, importers, distributors, marketing authorisation holders, agents, representatives, consultants, promoters or sponsors of any NAFDAC-regulated product in Nigeria.

The agency stated that the blacklist would remain in force until otherwise directed by its management, stressing that it reserves the right to take further regulatory, administrative, enforcement and legal actions where necessary to safeguard public health and preserve the integrity of Nigeria’s medicines regulatory system.

Reaffirming its commitment to maintaining the highest standards of regulatory compliance, NAFDAC urged stakeholders in the pharmaceutical sector to strictly adhere to applicable laws and regulatory requirements.

“The Agency remains resolute in ensuring that only safe, quality and properly regulated medical products are available to the Nigerian public,” the statement added.